-
Innovation Ranking
Innovation Ranking – Aclaris Therapeutics Inc
Aclaris Therapeutics Inc (Aclaris Therapeutics) is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company's pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Atopic Dermatitis (Atopic Eczema) Drug Details: ATI-2138...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Psoriasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Psoriasis Drug Details: ATI-2138 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Ulcerative Colitis Drug Details: ATI-2138 is under development for...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Favezelimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Favezelimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewAlopecia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Alopecia - Global Clinical Trials Review, 2024" provides an overview of Alopecia Clinical trials scenario. This report provides top line data relating to the clinical trials on Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ipilimumab in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ipilimumab in Soft Tissue Sarcoma Drug Details: Ipilimumab (Yervoy, Winglore)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lepzacitinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepzacitinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepzacitinib in Atopic Dermatitis (Atopic Eczema) Drug Details: ATI-1777 is...
-
Company Insights
Innovation and Patenting activity of Aclaris Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aclaris Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewDermatosis – Drugs In Development, 2024
Empower your strategies with our Dermatosis – Drugs In Development, 2024 report and make more profitable business decisions. A dermatosis is any skin defect or lesion on the skin that doesn’t cause inflammation. Atopic dermatitis, contact dermatitis, and seborrheic dermatitis are some common types of dermatoses. Some common causes of dermatosis include autoimmune disorders, psoriasis, atopic dermatitis, acne, and dermatophytosis. Symptoms include itchy and dry skin, rashes, blistering, oozing, crusting, and flaking. Treatments for dermatosis depend on the cause. It can...